Gemphire sinks on Phase IIb gemcabene data in hypercholesterolemia
By Chris Lieu | Aug 7, 2017 | 10:27 PM GMT
Gemphire Therapeutics Inc. (NASDAQ:GEMP) plummeted $8.73 (47%) to $9.93 on Monday after it reported preliminary Phase IIb data for its lead candidate gemcabene (CI-1027) to treat hypercholesterolemia in which
Read the full 295 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury